Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma

The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. Sixty-nine patients diagnosed with primary vaginal carcinoma (1975–2002) were included in the study. Detection of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Gynecologic oncology Jg. 129; H. 2; S. 406 - 411
Hauptverfasser: Larsson, Gabriella Lillsunde, Helenius, Gisela, Andersson, Sören, Sorbe, Bengt, Karlsson, Mats G.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States Elsevier Inc 01.05.2013
Schlagworte:
ISSN:0090-8258, 1095-6859, 1095-6859
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. Sixty-nine patients diagnosed with primary vaginal carcinoma (1975–2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing. 53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3.341; p=0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p=0.0002; p=0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate. HPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis. ► We investigate the HPV-distribution and impact on prognosis in vaginal carcinoma. ► Survival is better for patients with HPV-positive tumors. ► HPV-16 indicates better survival compared to other HPV-genotypes.
AbstractList AbstractObjectiveThe objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. MethodsSixty-nine patients diagnosed with primary vaginal carcinoma (1975–2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing. Results53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N = 26). Other HPV-types were HPV-18 (N = 2), HPV-31 (N = 2), HPV-33 (N = 2), HPV-45 (N = 1), HPV-52 (N = 2), HPV-56 (N = 1) and HPV-58 (N = 1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N = 13) and E-G350 (N = 11). Patients with HPV-positive tumors (N = 37) had a significantly (log-rank test = 3.341; p= 0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate ( p= 0.0002; p= 0.0004), compared with patients with HPV-negative tumors (N = 32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate. ConclusionsHPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis.
The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis.OBJECTIVEThe objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis.Sixty-nine patients diagnosed with primary vaginal carcinoma (1975-2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing.METHODSSixty-nine patients diagnosed with primary vaginal carcinoma (1975-2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing.53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3.341; p=0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p=0.0002; p=0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate.RESULTS53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3.341; p=0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p=0.0002; p=0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate.HPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis.CONCLUSIONSHPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis.
Objective The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. Methods Sixty-nine patients diagnosed with primary vaginal carcinoma (1975-2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing. Results 53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3341; p = 0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p = 0.0002; p = 0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate. Conclusions HPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis.
The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. Sixty-nine patients diagnosed with primary vaginal carcinoma (1975–2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing. 53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3.341; p=0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p=0.0002; p=0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate. HPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis. ► We investigate the HPV-distribution and impact on prognosis in vaginal carcinoma. ► Survival is better for patients with HPV-positive tumors. ► HPV-16 indicates better survival compared to other HPV-genotypes.
The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as HPV16-variant impact on prognosis. Sixty-nine patients diagnosed with primary vaginal carcinoma (1975-2002) were included in the study. Detection of twelve high-risk HPV (hr HPV) and two low-risk HPV (lr HPV) was performed with realtime-PCR. Samples positive for HPV-16 were analyzed for variants in the E6-gene with PCR and pyrosequencing. 53.6% (37/69) of the tumors were found to be HPV-positive, mostly for HPV-16 (N=26). Other HPV-types were HPV-18 (N=2), HPV-31 (N=2), HPV-33 (N=2), HPV-45 (N=1), HPV-52 (N=2), HPV-56 (N=1) and HPV-58 (N=1). Only European subtypes of HPV-16 were represented and the two most common HPV-16-variants were E-p (N=13) and E-G350 (N=11). Patients with HPV-positive tumors (N=37) had a significantly (log-rank test=3.341; p=0.0008) superior 5-year overall survival rate as well as cancer-specific survival rate and progression-free survival rate (p=0.0002; p=0.0004), compared with patients with HPV-negative tumors (N=32). Interestingly, patients with HPV-16-positive tumors had a superior overall survival compared with patients with tumors containing other HPV-genotypes. In a Cox proportional multivariate analysis age, tumor size, and HPV-status were independent and significant prognostic factors with regard to overall survival rate. HPV-status is of prognostic importance in vaginal carcinoma and varies with viral genotype. In this era of HPV-vaccination, genotypes other than those included in the vaccination program could still lead to vaginal carcinoma with unfavorable prognosis.
Author Andersson, Sören
Sorbe, Bengt
Helenius, Gisela
Karlsson, Mats G.
Larsson, Gabriella Lillsunde
Author_xml – sequence: 1
  givenname: Gabriella Lillsunde
  surname: Larsson
  fullname: Larsson, Gabriella Lillsunde
  email: gabriella.lillsunde-larsson@orebroll.se
  organization: Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden
– sequence: 2
  givenname: Gisela
  surname: Helenius
  fullname: Helenius, Gisela
  organization: Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden
– sequence: 3
  givenname: Sören
  surname: Andersson
  fullname: Andersson, Sören
  organization: Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden
– sequence: 4
  givenname: Bengt
  surname: Sorbe
  fullname: Sorbe, Bengt
  organization: Department of Oncology, Örebro University Hospital, Örebro, Sweden
– sequence: 5
  givenname: Mats G.
  surname: Karlsson
  fullname: Karlsson, Mats G.
  organization: Department of Laboratory Medicine, Örebro University Hospital, Örebro, Sweden
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23402906$$D View this record in MEDLINE/PubMed
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-29270$$DView record from Swedish Publication Index (Örebro universitet)
BookMark eNqFkl-L1DAUxYOsuLOrn0CQPK5gx5t0mjaIwrL-WWHBBXVfQ5re1oxtUpN2ZL69GWfchwWZh3Dhcn4ncM49IyfOOyTkOYMlAyZer5fbbuv8kgPLl8CXAKtHZMFAFpmoCnlCFgASsooX1Sk5i3ENADkw_oSc8nwFXIJYELwNvnM-TtZQO4zaTNS39Mc8aEdHPdq-94OmGxvmSC-ub-9e0g6dn7ajdR3VrqFplzFB41wfltbRje6s0z01OhjrksFT8rjVfcRnh3lOvn_88O3qOrv58unz1eVNZgohp4xJzpCLlajrhucStWRV26zauhKiKJoW61qwqmFVbkSr25xBA0UFZckq1iDy_Jy82vvG3zjOtRqDHXTYKq-tem_vLpUPXXqz4pKXkOQXe_kY_K8Z46QGGw32vXbo56hYzssyxSfKJH1xkM71gM29878kkyDfC0zwMQZs7yUM1K4vtVZ_-1K7vhRwlfpKlHxAGTvpyXo3BW37I-zbPYsp0Y3FoKKx6Aw2NqCZVOPtEf7dA9701lmj-5-4xbj2c0glphRUTID6urum3TGxPB1SWchk8Ob_Bke__wNnQdri
CitedBy_id crossref_primary_10_1002_ijc_35105
crossref_primary_10_3892_mco_2017_1328
crossref_primary_10_1371_journal_pone_0179520
crossref_primary_10_1111_aogs_14260
crossref_primary_10_1007_s00432_025_06267_x
crossref_primary_10_1002_cam4_870
crossref_primary_10_1002_ijc_32078
crossref_primary_10_1097_PGP_0000000000000612
crossref_primary_10_1111_1469_0691_12420
crossref_primary_10_1371_journal_pone_0112839
crossref_primary_10_1111_jog_12638
crossref_primary_10_1016_j_ygyno_2020_05_683
crossref_primary_10_1016_j_brachy_2025_03_001
crossref_primary_10_1007_s13337_018_0479_8
crossref_primary_10_1016_j_jmoldx_2014_12_004
crossref_primary_10_5301_jbm_5000191
crossref_primary_10_1186_s13027_017_0167_0
crossref_primary_10_1007_s12032_017_0893_6
crossref_primary_10_1016_j_ejogrb_2023_02_003
crossref_primary_10_3892_ol_2021_13148
crossref_primary_10_1007_s13402_017_0331_y
crossref_primary_10_1016_j_ygyno_2015_11_023
crossref_primary_10_1371_journal_pone_0183816
crossref_primary_10_1097_LGT_0000000000000185
crossref_primary_10_1016_j_jcjo_2019_03_001
crossref_primary_10_3390_cancers15041046
crossref_primary_10_1016_j_pathophys_2017_09_004
crossref_primary_10_1038_s41598_024_84688_3
crossref_primary_10_1016_j_ijbiomac_2017_10_051
crossref_primary_10_1038_bjc_2014_32
Cites_doi 10.1097/PGP.0b013e3182184c7a
10.1016/j.virol.2010.10.039
10.1097/IGC.0b013e31821bc615
10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2
10.1016/j.oraloncology.2003.10.011
10.1097/IGC.0b013e31827670c4
10.1158/1055-9965.EPI-10-1187
10.1097/AOG.0b013e31819bd6e0
10.1016/j.ygyno.2009.12.031
10.1016/j.jviromet.2006.05.002
10.1016/j.ygyno.2008.07.045
10.1016/j.ygyno.2004.11.045
10.1093/jnci/djn011
10.1002/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6
10.1097/IGC.0b013e31826a0471
10.1038/nm0595-464
10.1128/JVI.71.3.2463-2472.1997
10.1016/0042-6822(91)90507-8
10.1016/j.ygyno.2011.12.449
10.1128/JVI.67.11.6413-6423.1993
10.1111/j.1349-7006.2007.00546.x
10.1155/2012/893275
10.1002/ijc.11261
10.1038/bjc.1995.388
10.1016/j.ijrobp.2009.09.021
10.1111/j.1600-0463.2010.02618.x
10.1038/sj.bjc.6600024
10.1097/01.AOG.0000245786.86267.80
10.1111/j.1365-2559.2010.03727.x
10.1158/1055-9965.EPI-05-0864
10.1128/JVI.69.12.7743-7753.1995
10.1016/j.jcv.2007.09.009
10.1128/JVI.78.21.11451-11460.2004
ContentType Journal Article
Copyright 2013 Elsevier Inc.
Elsevier Inc.
Copyright © 2013 Elsevier Inc. All rights reserved.
Copyright_xml – notice: 2013 Elsevier Inc.
– notice: Elsevier Inc.
– notice: Copyright © 2013 Elsevier Inc. All rights reserved.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
D91
DOI 10.1016/j.ygyno.2013.02.004
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
SwePub
SwePub Articles
SWEPUB Örebro universitet
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic


MEDLINE

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1095-6859
EndPage 411
ExternalDocumentID oai_DiVA_org_oru_29270
23402906
10_1016_j_ygyno_2013_02_004
S0090825813000759
1_s2_0_S0090825813000759
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations Sweden
GeographicLocations_xml – name: Sweden
GrantInformation_xml – fundername: Nyckelfonden at Örebro County Council
– fundername: Örebro Council Research Committee
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
1B1
1P~
1RT
1~.
1~5
29I
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
71M
8P~
9JM
AABNK
AAEDT
AAEDW
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AATTM
AAXKI
AAXUO
AAYWO
ABBQC
ABFNM
ABFRF
ABJNI
ABMAC
ABMZM
ABWVN
ABXDB
ACDAQ
ACGFO
ACGFS
ACIEU
ACLOT
ACRLP
ACRPL
ACVFH
ADBBV
ADCNI
ADEZE
ADFGL
ADMUD
ADNMO
AEBSH
AEFWE
AEIPS
AEKER
AENEX
AEUPX
AEVXI
AFFNX
AFJKZ
AFPUW
AFRHN
AFTJW
AFXIZ
AGHFR
AGQPQ
AGUBO
AGYEJ
AHHHB
AIEXJ
AIGII
AIIUN
AIKHN
AITUG
AJRQY
AJUYK
AKBMS
AKRWK
AKYEP
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
ANKPU
ANZVX
APXCP
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CAG
COF
CS3
DM4
DU5
EBS
EFBJH
EFKBS
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HED
HMK
HMO
HVGLF
HZ~
IH2
IHE
J1W
K-O
KOM
L7B
LG5
M29
M41
MO0
N9A
O-L
O9-
OAUVE
OQ.
OZT
P-8
P-9
P2P
PC.
PH~
Q38
R2-
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SES
SEW
SPCBC
SSH
SSZ
T5K
UDS
UHS
UV1
WUQ
X7M
XPP
Z5R
ZGI
ZMT
ZU3
ZXP
~G-
~HD
AACTN
AFCTW
AFKWA
AJOXV
AMFUW
RIG
AAIAV
ABLVK
ABYKQ
AHPSJ
AJBFU
LCYCR
9DU
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
ADTPV
AOWAS
D91
ID FETCH-LOGICAL-c569t-1921e2646bbd239ea918fd4fb86655dfebb618d183c6faf310d058077181dee23
ISICitedReferencesCount 34
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000318058600024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 0090-8258
1095-6859
IngestDate Tue Nov 04 16:56:38 EST 2025
Sun Sep 28 07:37:12 EDT 2025
Thu Apr 03 07:05:48 EDT 2025
Sat Nov 29 03:33:08 EST 2025
Tue Nov 18 22:24:47 EST 2025
Fri Feb 23 02:28:43 EST 2024
Sun Feb 23 10:19:21 EST 2025
Tue Oct 14 19:31:11 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Human papilloma virus
Prognosis
HPV-16-variants
Vaginal carcinoma
Language English
License https://www.elsevier.com/tdm/userlicense/1.0
Copyright © 2013 Elsevier Inc. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c569t-1921e2646bbd239ea918fd4fb86655dfebb618d183c6faf310d058077181dee23
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 23402906
PQID 1327725867
PQPubID 23479
PageCount 6
ParticipantIDs swepub_primary_oai_DiVA_org_oru_29270
proquest_miscellaneous_1327725867
pubmed_primary_23402906
crossref_primary_10_1016_j_ygyno_2013_02_004
crossref_citationtrail_10_1016_j_ygyno_2013_02_004
elsevier_sciencedirect_doi_10_1016_j_ygyno_2013_02_004
elsevier_clinicalkeyesjournals_1_s2_0_S0090825813000759
elsevier_clinicalkey_doi_10_1016_j_ygyno_2013_02_004
PublicationCentury 2000
PublicationDate 2013-05-01
PublicationDateYYYYMMDD 2013-05-01
PublicationDate_xml – month: 05
  year: 2013
  text: 2013-05-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Gynecologic oncology
PublicationTitleAlternate Gynecol Oncol
PublicationYear 2013
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Ho, Chan, Burk, Das, Fujinaga, Icenogle (bb0055) 1993; 67
Lindh, Gorander, Andersson, Horal, Mattsby-Balzer, Ryd (bb0100) 2007; 40
Smith, Backes, Hoots, Kurman, Pimenta (bb0010) 2009; 113
Wang, Lai, Huang, Chao, Chang, Chang (bb0160) 2010; 78
Larsson, Helenius, Andersson, Elgh, Sorbe, Karlsson (bb0040) 2012; 22
Hampl, Sarajuuri, Wentzensen, Bender, Kueppers (bb0180) 2006; 108
Gheit, Cornet, Clifford, Iftner, Munk, Tommasino (bb0110) 2011; 20
Hoffmann, Lohrey, Hunziker, Kahn, Schwarz (bb0115) 2004; 40
Kammer, Tommasino, Syrjanen, Delius, Hebling, Warthorst (bb0080) 2002; 86
Arends, Wyllie, Bird (bb0175) 1995; 72
Tavassoli, Devilee (bb0185) 2003
Li, Thompson, O'Brien, McNeil, Scolyer, Cossart (bb0125) 2003; 106
Munger, Baldwin, Edwards, Hayakawa, Nguyen, Owens (bb0130) 2004; 78
Creasman, Phillips, Menck (bb0005) 1998; 83
Lindell, Nasman, Jonsson, Ehrsson, Jacobsson, Danielsson (bb0030) 2010; 117
Swan, Rajeevan, Tortolero-Luna, Follen, Tucker, Unger (bb0070) 2005; 96
Butz, Geisen, Ullmann, Spitkovsky, Hoppe-Seyler (bb0140) 1996; 68
Castellsague (bb0025) 2008; 110
Ellis, Keating, Baird, Hounsell, Renouf, Rowe (bb0090) 1995; 1
Fuste, del Pino, Perez, Garcia, Torne, Pahisa (bb0020) 2010; 57
Narisawa-Saito, Kiyono (bb0135) 2007; 98
Alonso, Felix, Torne, Fuste, Del Pino, Castillo (bb0015) 2012; 125
Zehbe, Wilander, Delius, Tommasino (bb0085) 1998; 58
Yamada, Wheeler, Halpern, Stewart, Hildesheim, Jenison (bb0065) 1995; 69
Crook, Wrede, Vousden (bb0145) 1991; 6
Yamada, Manos, Peto, Greer, Munoz, Bosch (bb0060) 1997; 71
Grodzki, Besson, Clavel, Arslan, Franceschi, Birembaut (bb0075) 2006; 15
Swan, Limor, Duncan, Rajeevan, Unger (bb0105) 2006; 136
Pim, Banks (bb0200) 2010; 118
Villa, Schlegel (bb0170) 1991; 181
Tsimplaki, Argyri, Michala, Kouvousi, Apostolaki, Magiakos (bb0035) 2012; 2012
Huertas-Salgado, Martin-Gamez, Moreno, Murillo, Bravo, Villa (bb0050) 2010; 410
Hellman, Johansson, Andersson, Pettersson, Auer (bb0195) 2013; 23
Brunner, Grimm, Polterauer, Hefler, Stani, Heinze (bb0045) 2011; 21
Fakhry, Westra, Li, Cmelak, Ridge, Pinto (bb0120) 2008; 100
Choschzick, Hantaredja, Tennstedt, Gieseking, Wolber, Simon (bb0190) 2011; 30
Fuste (10.1016/j.ygyno.2013.02.004_bb0020) 2010; 57
Villa (10.1016/j.ygyno.2013.02.004_bb0170) 1991; 181
Smith (10.1016/j.ygyno.2013.02.004_bb0010) 2009; 113
Tavassoli (10.1016/j.ygyno.2013.02.004_bb0185) 2003
Arends (10.1016/j.ygyno.2013.02.004_bb0175) 1995; 72
Alonso (10.1016/j.ygyno.2013.02.004_bb0015) 2012; 125
Pim (10.1016/j.ygyno.2013.02.004_bb0200) 2010; 118
Castellsague (10.1016/j.ygyno.2013.02.004_bb0025) 2008; 110
Swan (10.1016/j.ygyno.2013.02.004_bb0105) 2006; 136
Lindh (10.1016/j.ygyno.2013.02.004_bb0100) 2007; 40
Lindell (10.1016/j.ygyno.2013.02.004_bb0030) 2010; 117
Zehbe (10.1016/j.ygyno.2013.02.004_bb0085) 1998; 58
Narisawa-Saito (10.1016/j.ygyno.2013.02.004_bb0135) 2007; 98
Ho (10.1016/j.ygyno.2013.02.004_bb0055) 1993; 67
Fakhry (10.1016/j.ygyno.2013.02.004_bb0120) 2008; 100
Gheit (10.1016/j.ygyno.2013.02.004_bb0110) 2011; 20
Hampl (10.1016/j.ygyno.2013.02.004_bb0180) 2006; 108
Creasman (10.1016/j.ygyno.2013.02.004_bb0005) 1998; 83
Tsimplaki (10.1016/j.ygyno.2013.02.004_bb0035) 2012; 2012
Larsson (10.1016/j.ygyno.2013.02.004_bb0040) 2012; 22
Kammer (10.1016/j.ygyno.2013.02.004_bb0080) 2002; 86
Li (10.1016/j.ygyno.2013.02.004_bb0125) 2003; 106
Wang (10.1016/j.ygyno.2013.02.004_bb0160) 2010; 78
Choschzick (10.1016/j.ygyno.2013.02.004_bb0190) 2011; 30
Grodzki (10.1016/j.ygyno.2013.02.004_bb0075) 2006; 15
Butz (10.1016/j.ygyno.2013.02.004_bb0140) 1996; 68
Hoffmann (10.1016/j.ygyno.2013.02.004_bb0115) 2004; 40
Brunner (10.1016/j.ygyno.2013.02.004_bb0045) 2011; 21
Munger (10.1016/j.ygyno.2013.02.004_bb0130) 2004; 78
Huertas-Salgado (10.1016/j.ygyno.2013.02.004_bb0050) 2010; 410
Yamada (10.1016/j.ygyno.2013.02.004_bb0060) 1997; 71
Swan (10.1016/j.ygyno.2013.02.004_bb0070) 2005; 96
Hellman (10.1016/j.ygyno.2013.02.004_bb0195) 2013; 23
Crook (10.1016/j.ygyno.2013.02.004_bb0145) 1991; 6
Ellis (10.1016/j.ygyno.2013.02.004_bb0090) 1995; 1
Yamada (10.1016/j.ygyno.2013.02.004_bb0065) 1995; 69
References_xml – volume: 21
  start-page: 923
  year: 2011
  end-page: 929
  ident: bb0045
  article-title: The prognostic role of human papillomavirus in patients with vaginal cancer
  publication-title: Int J Gynecol Cancer
– volume: 40
  start-page: 321
  year: 2007
  end-page: 324
  ident: bb0100
  article-title: Real-time Taqman PCR targeting 14 human papilloma virus types
  publication-title: J Clin Virol
– volume: 23
  start-page: 41
  year: 2013
  end-page: 51
  ident: bb0195
  article-title: Prognostic Significance of Cell Cycle- and Invasion-Related Molecular Markers and Genomic Instability in Primary Carcinoma of the Vagina
  publication-title: Int J Gynecol Cancer
– volume: 69
  start-page: 7743
  year: 1995
  end-page: 7753
  ident: bb0065
  article-title: Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments
  publication-title: J Virol
– volume: 78
  start-page: 11451
  year: 2004
  end-page: 11460
  ident: bb0130
  article-title: Mechanisms of human papillomavirus-induced oncogenesis
  publication-title: J Virol
– volume: 6
  start-page: 873
  year: 1991
  end-page: 875
  ident: bb0145
  article-title: p53 point mutation in HPV negative human cervical carcinoma cell lines
  publication-title: Oncogene
– volume: 136
  start-page: 166
  year: 2006
  end-page: 170
  ident: bb0105
  article-title: Human papillomavirus type 16 variant assignment by pyrosequencing
  publication-title: J Virol Methods
– volume: 410
  start-page: 201
  year: 2010
  end-page: 215
  ident: bb0050
  article-title: E6 molecular variants of human papillomavirus (HPV) type 16: an updated and unified criterion for clustering and nomenclature
  publication-title: Virology
– volume: 30
  start-page: 497
  year: 2011
  end-page: 504
  ident: bb0190
  article-title: Role of TP53 mutations in vulvar carcinomas
  publication-title: Int J Gynecol Pathol
– volume: 113
  start-page: 917
  year: 2009
  end-page: 924
  ident: bb0010
  article-title: Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors
  publication-title: Obstet Gynecol
– volume: 96
  start-page: 695
  year: 2005
  end-page: 700
  ident: bb0070
  article-title: Human papillomavirus type 16 E2 and E6/E7 variants
  publication-title: Gynecol Oncol
– volume: 15
  start-page: 820
  year: 2006
  end-page: 822
  ident: bb0075
  article-title: Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 108
  start-page: 1361
  year: 2006
  end-page: 1368
  ident: bb0180
  article-title: Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer
  publication-title: Obstet Gynecol
– volume: 22
  start-page: 1413
  year: 2012
  end-page: 1419
  ident: bb0040
  article-title: Human papillomavirus (HPV) and HPV 16-variant distribution in vulvar squamous cell carcinoma in Sweden
  publication-title: Int J Gynecol Cancer
– volume: 67
  start-page: 6413
  year: 1993
  end-page: 6423
  ident: bb0055
  article-title: The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations
  publication-title: J Virol
– volume: 78
  start-page: 1111
  year: 2010
  end-page: 1120
  ident: bb0160
  article-title: Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy
  publication-title: Int J Radiat Oncol Biol Phys
– volume: 117
  start-page: 312
  year: 2010
  end-page: 316
  ident: bb0030
  article-title: Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node
  publication-title: Gynecol Oncol
– volume: 58
  start-page: 829
  year: 1998
  end-page: 833
  ident: bb0085
  article-title: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype
  publication-title: Cancer Res
– volume: 110
  start-page: S4
  year: 2008
  end-page: S7
  ident: bb0025
  article-title: Natural history and epidemiology of HPV infection and cervical cancer
  publication-title: Gynecol Oncol
– volume: 98
  start-page: 1505
  year: 2007
  end-page: 1511
  ident: bb0135
  article-title: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins
  publication-title: Cancer Sci
– volume: 125
  start-page: 194
  year: 2012
  end-page: 199
  ident: bb0015
  article-title: Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina
  publication-title: Gynecol Oncol
– volume: 1
  start-page: 464
  year: 1995
  end-page: 470
  ident: bb0090
  article-title: The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer
  publication-title: Nat Med
– volume: 100
  start-page: 261
  year: 2008
  end-page: 269
  ident: bb0120
  article-title: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
  publication-title: J Natl Cancer Inst
– volume: 72
  start-page: 646
  year: 1995
  end-page: 649
  ident: bb0175
  article-title: Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16
  publication-title: Br J Cancer
– volume: 118
  start-page: 471
  year: 2010
  end-page: 493
  ident: bb0200
  article-title: Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses
  publication-title: APMIS
– volume: 40
  start-page: 520
  year: 2004
  end-page: 524
  ident: bb0115
  article-title: Human papillomavirus type 16 E6 and E7 genotypes in head-and-neck carcinomas
  publication-title: Oral Oncol
– volume: 68
  start-page: 506
  year: 1996
  end-page: 513
  ident: bb0140
  article-title: Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis
  publication-title: Int J Cancer
– volume: 181
  start-page: 374
  year: 1991
  end-page: 377
  ident: bb0170
  article-title: Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region
  publication-title: Virology
– volume: 71
  start-page: 2463
  year: 1997
  end-page: 2472
  ident: bb0060
  article-title: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective
  publication-title: J Virol
– volume: 57
  start-page: 907
  year: 2010
  end-page: 916
  ident: bb0020
  article-title: Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16(INK4A) overexpression and clinicopathological correlations
  publication-title: Histopathology
– year: 2003
  ident: bb0185
  article-title: Tumours of the breast and female genital organs
  publication-title: World Health Organization Classification of Tumours
– volume: 2012
  start-page: 893275
  year: 2012
  ident: bb0035
  article-title: Human papillomavirus genotyping and e6/e7 mRNA expression in Greek women with intraepithelial neoplasia and squamous cell carcinoma of the vagina and vulva
  publication-title: J Oncol
– volume: 20
  start-page: 1315
  year: 2011
  end-page: 1321
  ident: bb0110
  article-title: Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women
  publication-title: Cancer Epidemiol Biomarkers Prev
– volume: 86
  start-page: 269
  year: 2002
  end-page: 273
  ident: bb0080
  article-title: Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease
  publication-title: Br J Cancer
– volume: 83
  start-page: 1033
  year: 1998
  end-page: 1040
  ident: bb0005
  article-title: The National Cancer Data Base report on cancer of the vagina
  publication-title: Cancer
– volume: 106
  start-page: 553
  year: 2003
  end-page: 558
  ident: bb0125
  article-title: Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil
  publication-title: Int J Cancer
– volume: 58
  start-page: 829
  year: 1998
  ident: 10.1016/j.ygyno.2013.02.004_bb0085
  article-title: Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype
  publication-title: Cancer Res
– volume: 30
  start-page: 497
  year: 2011
  ident: 10.1016/j.ygyno.2013.02.004_bb0190
  article-title: Role of TP53 mutations in vulvar carcinomas
  publication-title: Int J Gynecol Pathol
  doi: 10.1097/PGP.0b013e3182184c7a
– volume: 410
  start-page: 201
  year: 2010
  ident: 10.1016/j.ygyno.2013.02.004_bb0050
  article-title: E6 molecular variants of human papillomavirus (HPV) type 16: an updated and unified criterion for clustering and nomenclature
  publication-title: Virology
  doi: 10.1016/j.virol.2010.10.039
– volume: 21
  start-page: 923
  year: 2011
  ident: 10.1016/j.ygyno.2013.02.004_bb0045
  article-title: The prognostic role of human papillomavirus in patients with vaginal cancer
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0b013e31821bc615
– volume: 68
  start-page: 506
  year: 1996
  ident: 10.1016/j.ygyno.2013.02.004_bb0140
  article-title: Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis
  publication-title: Int J Cancer
  doi: 10.1002/(SICI)1097-0215(19961115)68:4<506::AID-IJC17>3.0.CO;2-2
– volume: 40
  start-page: 520
  year: 2004
  ident: 10.1016/j.ygyno.2013.02.004_bb0115
  article-title: Human papillomavirus type 16 E6 and E7 genotypes in head-and-neck carcinomas
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2003.10.011
– volume: 23
  start-page: 41
  issue: 1
  year: 2013
  ident: 10.1016/j.ygyno.2013.02.004_bb0195
  article-title: Prognostic Significance of Cell Cycle- and Invasion-Related Molecular Markers and Genomic Instability in Primary Carcinoma of the Vagina
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0b013e31827670c4
– volume: 20
  start-page: 1315
  year: 2011
  ident: 10.1016/j.ygyno.2013.02.004_bb0110
  article-title: Risks for persistence and progression by human papillomavirus type 16 variant lineages among a population-based sample of Danish women
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-10-1187
– volume: 113
  start-page: 917
  year: 2009
  ident: 10.1016/j.ygyno.2013.02.004_bb0010
  article-title: Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors
  publication-title: Obstet Gynecol
  doi: 10.1097/AOG.0b013e31819bd6e0
– volume: 117
  start-page: 312
  year: 2010
  ident: 10.1016/j.ygyno.2013.02.004_bb0030
  article-title: Presence of human papillomavirus (HPV) in vulvar squamous cell carcinoma (VSCC) and sentinel node
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2009.12.031
– volume: 136
  start-page: 166
  year: 2006
  ident: 10.1016/j.ygyno.2013.02.004_bb0105
  article-title: Human papillomavirus type 16 variant assignment by pyrosequencing
  publication-title: J Virol Methods
  doi: 10.1016/j.jviromet.2006.05.002
– volume: 110
  start-page: S4
  year: 2008
  ident: 10.1016/j.ygyno.2013.02.004_bb0025
  article-title: Natural history and epidemiology of HPV infection and cervical cancer
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2008.07.045
– year: 2003
  ident: 10.1016/j.ygyno.2013.02.004_bb0185
  article-title: Tumours of the breast and female genital organs
– volume: 96
  start-page: 695
  year: 2005
  ident: 10.1016/j.ygyno.2013.02.004_bb0070
  article-title: Human papillomavirus type 16 E2 and E6/E7 variants
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2004.11.045
– volume: 100
  start-page: 261
  year: 2008
  ident: 10.1016/j.ygyno.2013.02.004_bb0120
  article-title: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djn011
– volume: 83
  start-page: 1033
  year: 1998
  ident: 10.1016/j.ygyno.2013.02.004_bb0005
  article-title: The National Cancer Data Base report on cancer of the vagina
  publication-title: Cancer
  doi: 10.1002/(SICI)1097-0142(19980901)83:5<1033::AID-CNCR30>3.0.CO;2-6
– volume: 22
  start-page: 1413
  year: 2012
  ident: 10.1016/j.ygyno.2013.02.004_bb0040
  article-title: Human papillomavirus (HPV) and HPV 16-variant distribution in vulvar squamous cell carcinoma in Sweden
  publication-title: Int J Gynecol Cancer
  doi: 10.1097/IGC.0b013e31826a0471
– volume: 1
  start-page: 464
  year: 1995
  ident: 10.1016/j.ygyno.2013.02.004_bb0090
  article-title: The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer
  publication-title: Nat Med
  doi: 10.1038/nm0595-464
– volume: 6
  start-page: 873
  year: 1991
  ident: 10.1016/j.ygyno.2013.02.004_bb0145
  article-title: p53 point mutation in HPV negative human cervical carcinoma cell lines
  publication-title: Oncogene
– volume: 71
  start-page: 2463
  year: 1997
  ident: 10.1016/j.ygyno.2013.02.004_bb0060
  article-title: Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective
  publication-title: J Virol
  doi: 10.1128/JVI.71.3.2463-2472.1997
– volume: 181
  start-page: 374
  year: 1991
  ident: 10.1016/j.ygyno.2013.02.004_bb0170
  article-title: Differences in transformation activity between HPV-18 and HPV-16 map to the viral LCR-E6-E7 region
  publication-title: Virology
  doi: 10.1016/0042-6822(91)90507-8
– volume: 125
  start-page: 194
  year: 2012
  ident: 10.1016/j.ygyno.2013.02.004_bb0015
  article-title: Human papillomavirus as a favorable prognostic biomarker in squamous cell carcinomas of the vagina
  publication-title: Gynecol Oncol
  doi: 10.1016/j.ygyno.2011.12.449
– volume: 67
  start-page: 6413
  year: 1993
  ident: 10.1016/j.ygyno.2013.02.004_bb0055
  article-title: The genetic drift of human papillomavirus type 16 is a means of reconstructing prehistoric viral spread and the movement of ancient human populations
  publication-title: J Virol
  doi: 10.1128/JVI.67.11.6413-6423.1993
– volume: 98
  start-page: 1505
  year: 2007
  ident: 10.1016/j.ygyno.2013.02.004_bb0135
  article-title: Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins
  publication-title: Cancer Sci
  doi: 10.1111/j.1349-7006.2007.00546.x
– volume: 2012
  start-page: 893275
  year: 2012
  ident: 10.1016/j.ygyno.2013.02.004_bb0035
  article-title: Human papillomavirus genotyping and e6/e7 mRNA expression in Greek women with intraepithelial neoplasia and squamous cell carcinoma of the vagina and vulva
  publication-title: J Oncol
  doi: 10.1155/2012/893275
– volume: 106
  start-page: 553
  year: 2003
  ident: 10.1016/j.ygyno.2013.02.004_bb0125
  article-title: Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil
  publication-title: Int J Cancer
  doi: 10.1002/ijc.11261
– volume: 72
  start-page: 646
  year: 1995
  ident: 10.1016/j.ygyno.2013.02.004_bb0175
  article-title: Human papillomavirus type 18 is associated with less apoptosis in fibroblast tumours than human papillomavirus type 16
  publication-title: Br J Cancer
  doi: 10.1038/bjc.1995.388
– volume: 78
  start-page: 1111
  year: 2010
  ident: 10.1016/j.ygyno.2013.02.004_bb0160
  article-title: Clinical effect of human papillomavirus genotypes in patients with cervical cancer undergoing primary radiotherapy
  publication-title: Int J Radiat Oncol Biol Phys
  doi: 10.1016/j.ijrobp.2009.09.021
– volume: 118
  start-page: 471
  issue: 6–
  year: 2010
  ident: 10.1016/j.ygyno.2013.02.004_bb0200
  article-title: Interaction of viral oncoproteins with cellular target molecules: infection with high-risk vs low-risk human papillomaviruses
  publication-title: APMIS
  doi: 10.1111/j.1600-0463.2010.02618.x
– volume: 86
  start-page: 269
  year: 2002
  ident: 10.1016/j.ygyno.2013.02.004_bb0080
  article-title: Variants of the long control region and the E6 oncogene in European human papillomavirus type 16 isolates: implications for cervical disease
  publication-title: Br J Cancer
  doi: 10.1038/sj.bjc.6600024
– volume: 108
  start-page: 1361
  year: 2006
  ident: 10.1016/j.ygyno.2013.02.004_bb0180
  article-title: Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer
  publication-title: Obstet Gynecol
  doi: 10.1097/01.AOG.0000245786.86267.80
– volume: 57
  start-page: 907
  year: 2010
  ident: 10.1016/j.ygyno.2013.02.004_bb0020
  article-title: Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16(INK4A) overexpression and clinicopathological correlations
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2010.03727.x
– volume: 15
  start-page: 820
  year: 2006
  ident: 10.1016/j.ygyno.2013.02.004_bb0075
  article-title: Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variant
  publication-title: Cancer Epidemiol Biomarkers Prev
  doi: 10.1158/1055-9965.EPI-05-0864
– volume: 69
  start-page: 7743
  year: 1995
  ident: 10.1016/j.ygyno.2013.02.004_bb0065
  article-title: Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments
  publication-title: J Virol
  doi: 10.1128/JVI.69.12.7743-7753.1995
– volume: 40
  start-page: 321
  year: 2007
  ident: 10.1016/j.ygyno.2013.02.004_bb0100
  article-title: Real-time Taqman PCR targeting 14 human papilloma virus types
  publication-title: J Clin Virol
  doi: 10.1016/j.jcv.2007.09.009
– volume: 78
  start-page: 11451
  year: 2004
  ident: 10.1016/j.ygyno.2013.02.004_bb0130
  article-title: Mechanisms of human papillomavirus-induced oncogenesis
  publication-title: J Virol
  doi: 10.1128/JVI.78.21.11451-11460.2004
SSID ssj0003012
Score 2.2390308
Snippet The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well as...
AbstractObjectiveThe objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as...
Objective The objectives of this study are to investigate the human papilloma virus (HPV) distribution in vaginal cancer and to evaluate HPV-genotype as well...
SourceID swepub
proquest
pubmed
crossref
elsevier
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 406
SubjectTerms Adenocarcinoma - mortality
Adenocarcinoma - radiotherapy
Adenocarcinoma - virology
Adult
Aged
Aged, 80 and over
Alphapapillomavirus - classification
Alphapapillomavirus - genetics
Alphapapillomavirus - isolation & purification
Biomedicin
Biomedicine
Brachytherapy
Carcinoma, Squamous Cell - mortality
Carcinoma, Squamous Cell - radiotherapy
Carcinoma, Squamous Cell - virology
DNA, Viral - analysis
DNA, Viral - isolation & purification
Female
Follow-Up Studies
Genetic Markers
Genotype
Genotyping Techniques
Hematology, Oncology, and Palliative Medicine
HPV-16-variants
Human papilloma virus
Human papillomavirus 16 - classification
Human papillomavirus 16 - genetics
Human papillomavirus 16 - isolation & purification
Human Papillomavirus DNA Tests
Humans
Middle Aged
Multivariate Analysis
Obstetrics and Gynecology
Oncogene Proteins, Viral - genetics
Papillomavirus Infections - complications
Papillomavirus Infections - virology
Prognosis
Real-Time Polymerase Chain Reaction
Repressor Proteins - genetics
Survival Analysis
Sweden
Vaginal carcinoma
Vaginal Neoplasms - mortality
Vaginal Neoplasms - radiotherapy
Vaginal Neoplasms - virology
Title Prognostic impact of human papilloma virus (HPV) genotyping and HPV-16 subtyping in vaginal carcinoma
URI https://www.clinicalkey.com/#!/content/1-s2.0-S0090825813000759
https://www.clinicalkey.es/playcontent/1-s2.0-S0090825813000759
https://dx.doi.org/10.1016/j.ygyno.2013.02.004
https://www.ncbi.nlm.nih.gov/pubmed/23402906
https://www.proquest.com/docview/1327725867
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-29270
Volume 129
WOSCitedRecordID wos000318058600024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVESC
  databaseName: Elsevier SD Freedom Collection Journals 2021
  customDbUrl:
  eissn: 1095-6859
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0003012
  issn: 1095-6859
  databaseCode: AIEXJ
  dateStart: 19950101
  isFulltext: true
  titleUrlDefault: https://www.sciencedirect.com
  providerName: Elsevier
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLa6DSFeEHfKZTISIFAJyj3OYwfdBiql0rqpb1biOFWm4pS2qdYfxP_kOHaSQscYDzw0qtwkTu0v52af7yD0MmYBTzxmGZKIxHA9Yhlx6qVGEjLQJ6EjOQnLYhPBYEDG43DYav2ocmFW00AIcnERzv7rVEMbTLZMnf2H6a5vCg3wHSYdjjDtcLzWxA_nudw8J4lYmxRIVYpvFs2y6TT_FnVW2bwo463HwzMZGJBUrcv1rMpYhFbD8juLItaNmeisIlVBi8nqQyLX8lzbtUdrwZmSo51csF9i9X3wnXVe11EUg2sOyOv04UFkcmCDK6n_skIF6mUNqFpfdMv8G32HE7myf-BvZLCd5PO4jMoecDFZbkYxrI09g1rwgqln-ESzg_NL2ipprQMk2YbXrGSvW1IXbOsEFZ44f7-erIVM97QcxdLqNiqwWvYffKWHp_0-HfXGo9ez74YsTiYX8XWllh20ZwdeCMJzr_upN_5cq3yQkmpZXT9wRW9VbiTc6vdPJtC2i_Mbf21p84zuoNvaWcFdBbK7qMXFPXTzi96OcR_xBmtYYQ3nKS6xhmus4RJr-A1g6i1ucIYBZ1jhDNc4w5nAGme4xtkDdHrYG304NnTdDoN5frg0JMUeB0Pbj-PEdkIehRZJEzeNJbeil6Q8jn2LJKBMmJ9GKTgYiekRMwAzyUo4t52HaFfkgj9GOHIIWPAWM4OUu5GdkoS5hDkRS30WuiRtI7saSso0qb2srTKl1e7Fc1qOP5XjT02bwvi30bv6opnidLn6dLeaI1qlK4OCpYCvqy8LLruML7SsWFCLLuBMegJujgzUELmyDBZ82EZ-faW2g5V9-_cuX1QQoqAl5NJfJHheQFeODW60R_ygjR4pbNV_3XZcUxZ9aKNXCmz1L5J6_mN21qX5fAKfgtqhHZhPrtHLU3Srecufod3lvODP0Q22WmaL-T7aCcZkX79EPwEj4_bT
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+impact+of+human+papilloma+virus+%28HPV%29+genotyping+and+HPV-16+subtyping+in+vaginal+carcinoma&rft.jtitle=Gynecologic+oncology&rft.au=Larsson%2C+Gabriella+Lillsunde&rft.au=Helenius%2C+Gisela&rft.au=Andersson%2C+S%C3%B6ren&rft.au=Sorbe%2C+Bengt&rft.date=2013-05-01&rft.issn=1095-6859&rft.eissn=1095-6859&rft.volume=129&rft.issue=2&rft.spage=406&rft_id=info:doi/10.1016%2Fj.ygyno.2013.02.004&rft.externalDBID=NO_FULL_TEXT
thumbnail_m http://cvtisr.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F00908258%2FS0090825813X00046%2Fcov150h.gif